tradingkey.logo

Neuronetics Inc

STIM
查看詳細走勢圖
1.560USD
+0.140+9.86%
收盤 02/06, 16:00美東報價延遲15分鐘
106.77M總市值
虧損本益比TTM

Neuronetics Inc

1.560
+0.140+9.86%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+9.86%

5天

-25.36%

1月

-20.41%

6月

-62.23%

今年開始到現在

+13.04%

1年

-49.19%

查看詳細走勢圖

TradingKey Neuronetics Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Neuronetics Inc當前公司基本面數據相對穩定,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在醫療設備與耗材行業排名89/205位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為6.50。中期看,股價處於下降通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Neuronetics Inc評分

相關信息

行業排名
89 / 205
全市場排名
239 / 4521
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Neuronetics Inc亮點

亮點風險
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
業績增長期
公司處於發展階段,最新年度總收入74.89M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入74.89M美元
估值合理
公司最新PE估值-1.88,處於3年歷史合理位
機構減倉
最新機構持股42.40M股,環比減少26.69%
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉13.74K股
活躍度增加
近期活躍度增加,過去20天平均換手率0.95

分析師目標

基於 3 分析師
買入
評級
6.500
目標均價
+319.35%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Neuronetics Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Neuronetics Inc簡介

Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
公司代碼STIM
公司Neuronetics Inc
CEOMr. Keith J. Sullivan
網址https://neurostar.com/neuronetics/
KeyAI